Neuroleptic malignant syndrome.
Neuroleptic malignant syndrome is a rare, idiosyncratic condition related to neuroleptic use which may develop at any stage during neuroleptic treatment and can prove fatal. Although most commonly seen in psychiatric patients, anyone prescribed a neuroleptic is at risk and it has been associated with other agents. This article discusses its recognition, risk factors, clinical course and treatment, together with a summary of current thinking on its aetiology.
Bristow
M F
MF
Cheam Resource Centre, St Helier Trust University Hospital, Surrey.
Kohen
D
D
D014150:Antipsychotic Agents / Q000009:adverse effects; D003937:Diagnosis, Differential; D018492:Dopamine Antagonists / Q000009:adverse effects; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D011954:Receptors, Dopamine / Q000187:drug effects; D012307:Risk Factors
D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D011954:Receptors, Dopamine